Atara Biotherapeutics stock fell 6.5 percent after the company announced details of its proposed secondary stock offering. The Bay Area company expects to raise $127.75 million with the sale of 7 million of its shares at $18.25 each, according to a filing with the Securities and Exchange Commission on Jan. 3. The offering is expected…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
